These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 29695174)
1. Preparation of psoralen polymer-lipid hybrid nanoparticles and their reversal of multidrug resistance in MCF-7/ADR cells. Huang Q; Cai T; Li Q; Huang Y; Liu Q; Wang B; Xia X; Wang Q; Whitney JCC; Cole SPC; Cai Y Drug Deliv; 2018 Nov; 25(1):1056-1066. PubMed ID: 29695174 [TBL] [Abstract][Full Text] [Related]
2. Polymer-lipid hybrid nanoparticles: A novel drug delivery system for enhancing the activity of Psoralen against breast cancer. Du M; Ouyang Y; Meng F; Zhang X; Ma Q; Zhuang Y; Liu H; Pang M; Cai T; Cai Y Int J Pharm; 2019 Apr; 561():274-282. PubMed ID: 30851393 [TBL] [Abstract][Full Text] [Related]
3. Fabrication of psoralen-loaded lipid-polymer hybrid nanoparticles and their reversal effect on drug resistance of cancer cells. Yuan Y; Chiba P; Cai T; Callaghan R; Bai L; Cole SPC; Cai Y Oncol Rep; 2018 Aug; 40(2):1055-1063. PubMed ID: 29901161 [TBL] [Abstract][Full Text] [Related]
4. Dual agent loaded PLGA nanoparticles enhanced antitumor activity in a multidrug-resistant breast tumor eenograft model. Chen Y; Zheng XL; Fang DL; Yang Y; Zhang JK; Li HL; Xu B; Lei Y; Ren K; Song XR Int J Mol Sci; 2014 Feb; 15(2):2761-72. PubMed ID: 24552875 [TBL] [Abstract][Full Text] [Related]
5. Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells. Yuan Y; Cai T; Callaghan R; Li Q; Huang Y; Wang B; Huang Q; Du M; Ma Q; Chiba P; Cai Y Int J Nanomedicine; 2019; 14():2207-2218. PubMed ID: 30988617 [TBL] [Abstract][Full Text] [Related]
6. An all-in-one nanoparticle for overcoming drug resistance: doxorubicin and elacridar co-loaded folate receptor targeted PLGA/MSN hybrid nanoparticles. Tonbul H; Şahin A; Öztürk SC; Ultav G; Tavukçuoğlu E; Akbaş S; Aktaş Y; Esendağlı G; Çapan Y J Drug Target; 2024 Nov; 32(9):1101-1110. PubMed ID: 38946465 [TBL] [Abstract][Full Text] [Related]
7. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer. Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609 [TBL] [Abstract][Full Text] [Related]
8. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. Wong HL; Bendayan R; Rauth AM; Wu XY J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178 [TBL] [Abstract][Full Text] [Related]
9. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies. Li B; Xu H; Li Z; Yao M; Xie M; Shen H; Shen S; Wang X; Jin Y Int J Nanomedicine; 2012; 7():187-97. PubMed ID: 22275834 [TBL] [Abstract][Full Text] [Related]
10. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance. Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509 [TBL] [Abstract][Full Text] [Related]
11. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells. Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359 [TBL] [Abstract][Full Text] [Related]
12. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer. Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756 [TBL] [Abstract][Full Text] [Related]
13. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging. Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307 [TBL] [Abstract][Full Text] [Related]
14. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells. Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231 [TBL] [Abstract][Full Text] [Related]
15. Co-delivery of docetaxel and Poloxamer 235 by PLGA-TPGS nanoparticles for breast cancer treatment. Tang X; Liang Y; Feng X; Zhang R; Jin X; Sun L Mater Sci Eng C Mater Biol Appl; 2015 Apr; 49():348-355. PubMed ID: 25686959 [TBL] [Abstract][Full Text] [Related]
16. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy. Li X; Jia X; Niu H Int J Nanomedicine; 2018; 13():4107-4119. PubMed ID: 30034236 [TBL] [Abstract][Full Text] [Related]
17. PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3. Bol GM; Khan R; Heerma van Voss MR; Tantravedi S; Korz D; Kato Y; Raman V Cancer Chemother Pharmacol; 2015 Oct; 76(4):821-7. PubMed ID: 26330329 [TBL] [Abstract][Full Text] [Related]
18. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin. Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738 [TBL] [Abstract][Full Text] [Related]
19. Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment. Katiyar SS; Muntimadugu E; Rafeeqi TA; Domb AJ; Khan W Drug Deliv; 2016 Sep; 23(7):2608-2616. PubMed ID: 26036652 [TBL] [Abstract][Full Text] [Related]
20. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy. Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]